Affiliations: Russian Academy of Sciences, Engelhardt Institute of Molecular Biology, Moscow 119991, Russia
Correspondence:
[*]
Corresponding author: Vladimir Mikhailovich, Russian Academy of Sciences, Engelhardt Institute of Molecular Biology, 32 Vavilova Street, Moscow 119991, Russia. Tel.: +7 499 135 1177; Fax: +7 499 135 1405; E-mail:v.mikhailovich@gmail.com
Abstract: BACKGROUND: Improving the efficacy of anticancer therapy remains an urgent
and very important task. Screening of the individual genetic metabolism of
cancer patients allows for prescribing adequate medication in the correct
dose as well as for decreasing side effects associated with drug toxicity. OBJECTIVE: Estimation of a microarray-based method for genotyping of the
UGT1A1, DPYD, GSTP1, and ABCB1 metabolic regulation genes to evaluate for an increased risk of
toxicity of anticancer drugs. METHODS: The microarray was used to conduct genotyping of specimens taken
from 115 cancer patients and 31 healthy donors. RESULTS: A microarray-based method for identification of the rs8175347,
rs3918290, rs1695, and rs1045642 polymorphisms in the corresponding
UGT1A1, DPYD, GSTP1, and ABCB1 genes has been developed for genotyping. The results obtained were
in full concordance with those obtained using control sequencing. The
frequencies of the rs8175347, rs3918290, rs1695, and rs1045642 genetic
variations were 0.38, 0, 0.35, and 0.56, respectively. CONCLUSION: The implementation of this biochip-based method in diagnostic
practice should increase the overall survival and quality of life of cancer
patients, decrease the length of their hospital stay, and reduce treatment
costs.
